Grail (NASDAQ:GRAL – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.
Valuation & Earnings
This table compares Grail and Viridian Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Grail | $125.60 million | 10.32 | N/A | N/A | N/A |
| Viridian Therapeutics | $302,000.00 | 4,073.44 | -$237.73 million | ($3.77) | -4.12 |
Grail has higher revenue and earnings than Viridian Therapeutics.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Grail | 0 | 3 | 0 | 0 | 2.00 |
| Viridian Therapeutics | 0 | 3 | 9 | 0 | 2.75 |
Grail currently has a consensus target price of $16.00, indicating a potential downside of 58.51%. Viridian Therapeutics has a consensus target price of $35.70, indicating a potential upside of 129.88%. Given Viridian Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than Grail.
Profitability
This table compares Grail and Viridian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Grail | N/A | N/A | N/A |
| Viridian Therapeutics | -85,127.16% | -70.12% | -41.49% |
About Grail
GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
About Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.
